Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Contribution of the Epstein-Barr Virus and the Tumour Microenvironment to Anti-Apoptotic Mechanisms in DLBCL (CoMAnD)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Ireland,Australia
Call: MSCA Postdoctoral Fellowships 2021 (HORIZON-MSCA-2021-PF-01, 2021)
Start date: 2023-01-03
End date: 2026-01-02
Duration (months): 36.0
Total project cost (EUR): 276864.48
EU funding (EUR): 276864.48
Participants: 2
Project status: TERMINATED

Diffuse large B-cell lymphoma (DLBCL) accounts for over one-third of lymphomas and is fatal in up to 40% of cases. Particularly poor survival is associated with DLBCL subtypes that over-express the oncogene MYC and contain the cancer-causing Epstein-Barr virus (EBV). These tumours frequently resist apoptosis, with a poorer response to chemotherapy. Recent evidence has strongly implicated a role for the tumour microenvironment (TME) in cancer progression; however, the relationship between EBV, MYC, and the TME in DLBCL remains poorly understood. CoMAnD aims to elucidate the synergistic relationship between EBV, MYC and the TME to explore how these oncogenic drivers converge to protect DLBCL tumours from apoptosis. This will be achieved using a new generation of EBV+ and EBV- DLBCL models to derive novel insights into the biology of EBV+ DLBCL. This will be coupled with state-of-the-art intravital imaging of tumour progression in humanised mice and highly multiplexed, spatially resolved, imaging of the TME in EBV+/- patient tumours. This will allow the study, in unprecedented detail, of the impact of viral and cellular oncogenic drivers on the TME and apoptosis in DLBCL. This research directly contributes to Cancer- and Infectious disease-related EU and UN goals, and will support the areas of Open Science, Gender Equality, and the Green Charter. The Fellow will spend 2 years at the Walter and Elisa Hall Institute of Medical Research (Australia) expanding her skills in in vitro disease mimetics, and acquiring a skillset in apoptotic pathways and intravital imaging. She will return to the University of Limerick (Ireland) and receive training in high-dimensional imaging and data analytics. The Fellow will be immersed within a multidisciplinary team with expertise in lymphomagenesis, virology, apoptosis and the TME; they will support her in meeting the research/training objectives and preparing for an independent career in the field of EBV-associated lymphomagenesis.

Keywords: epstein barr virus lymphoma
Teaching Lytic Polysaccharide Monooxygenases to do Cytochrome P450 Catalysis (NewCat)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Norway,Poland,Austria
Call: EIC Pathfinder Open 2021 (HORIZON-EIC-2021-PATHFINDEROPEN-01, 2021)
Start date: 2022-06-01
End date: 2025-05-31
Duration (months): 36.0
Total project cost (EUR): 2999772.5
EU funding (EUR): 2999772.5
Participants: 4
Project status: SIGNED

Lytic polysaccharide monooxygenases (LPMO) and cytochrome P450 (CYP) are copper- and iron-dependent, respectively, enzymatic systems that perform regio- and stereospecific oxidation of non-activated hydrocarbons in Nature. To control such reactions in modern industry and biotechnology is of utmost importance in creating products of value such as secondgeneration bioethanol and products of value for i.e. the pharmaceutical industry. Due to the major drawbacks of using CYPs, including their partially membrane bound nature and the requirement of a reductase in combination with reducing agents such as NAD(P)H to transfer electrons to the active site for oxygen activation, it is highly desirable to develop new type of catalyst that can perform the same type of reactions. An attractive alternative strategy is to engineer LPMOs to perform CYP catalysis. LPMOs are small, robust, easy to produce in large scale, and rigid water-soluble proteins with a plethora of electron donors. The extended, flat LPMO surface, with huge natural sequence variation and thus, likely, mutability, provides a fantastic scaffold for engineering access to the active site as well as substrate affinity. We propose to use LPMOs engineered to accommodate typical CYP substrates and immobilize this on solid supports to provide confinement necessary in bringing the oxygen species together with the C-H bond to be oxidized in a tailored, "closed" environment. Moreover, the rate of LPMO catalysis can be greatly enhanced compared to traditional CYP catalysis by the addition H2O2 in the presence of low, priming concentrations of an external reductant to achieve efficiency constants (kcat/Km) in the order of 106 M-1s-1, which is typical for peroxygenases. The proposed ground-breaking research fits excellently well with the work program "Future and Emerging Technologies" where the goal is to challenge current thinking.

Keywords: lytic polysaccharide monooxygenases,cytochrome p450,hybrid nano catalysts,enzyme immobilization,high tech biotechnology,oxidation,fine compounds chemistry
Potentials of Agroecological practices in east Africa with a focus on Circular water-energy-nutrient systems (PrAEctiCe)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Food, Bioeconomy Natural Resources, Agriculture and Environment
Theme: Bio-Environment
Destination: Fair, healthy and environmentally-friendly food systems from primary production to consumption
Action type: Research and Innovation actions
Countries involved: Germany,Malta,Sweden,Uganda,Slovenia,Kenya,Tanzania, United Republic of,Portugal,Nigeria
Call: Agro-ecological approaches in African agriculture systems (HORIZON-CL6-2022-FARM2FORK-01, 2022)
Start date: 2022-11-01
End date: 2026-04-30
Duration (months): 42.0
Total project cost (EUR): 6985275.01
EU funding (EUR): 6985275.0
Participants: 17
Project status: SIGNED

PrAEctiCe will provide a novel agro-ecology indicator set for East Africa, aimed at helping smallholder farmers in their agro-ecological transition. The project goes beyond the existing indicator frameworks by putting the “concept into action” with a decision support tool for agro-ecology advisors supporting the selection of the best suited combination of agro-ecological practices in a local context. In addition, it puts a focus on circular water-energy-nutrient systems of integrated aqua-agriculture, an practice with high potential for efficient farming with minimal climate impacts, which has not been sufficiently explored in previous indicator work. Through a multi-stakeholder approach, new insight on agro-ecological practices in East Africa will be gathered to inform on existing successful practices as well as the barriers and drivers of East African smallholder farmers. This insight will help develop an indicator framework for agro-ecology, which, while building on existing frameworks, is adapted to the East African context and captures integrated aqua-agriculture practices in detail. The PrAEctiCe decision support tool will then, at the farm level, help assess environmental and socio-economic impacts, with a particular focus on impacts on climate change mitigation and adaptation as well as financial viability. The tool will be validated in three living labs, situated in Kenya, Uganda and Tanzania, covering different integrated aqua-agriculture farming set-ups. Knowledge sharing activities through trainings, student exchanges and events, ensure the dissemination of results across East Africa and between AU and EU. To reach practitioners at every level, a cascade training mechanism with a train-the-trainer course will help agro-ecology advisors train farming representatives at the local level who then will help the farmers in their agro-ecological transition. Policy recommendations for AU and EU policies will round off the project.

Keywords: agro ecological farming practices,integrated aqua agriculture,east africa,impact assessment,decision support tool,multi stakeholder engagement,climate change,circularity
Security Assurance-driven AI-based Security Services for Trustworthy Security Engineering from Left-to-Right (SECASSURED)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Civil Security for Society
Theme: Civil Security for Society
Destination: Increased Cybersecurity
Action type: Innovation actions
Countries involved: Norway,Finland,Germany,Greece,France,Spain,Romania,Hungary,Bulgaria,Türkiye
Call: Approaches and tools for security in software and hardware development and assessment (HORIZON-CL3-2024-CS-01, 2024)
Start date: 2025-12-01
End date: 2028-11-30
Duration (months): 36.0
Total project cost (EUR): 6977057.74
EU funding (EUR): 5983954.92
Participants: 19
Project status: SIGNED

The more complex and critical that many systems becoming nowadays, the more they are developed by integrating different (sub-)components, even third-party hardware/software components. With the pressure of time to market, and the ever-evolving security threats, getting more complicated than ever with the breakthroughs in Generative Artificial Intelligence (GenAI), how to enable more secure development and integrations of critical systems to be assured for security? These huge challenges must be addressed to make “secure services, processes and products, as well as to robust digital infrastructures capable to resist and counter cyber-attacks and hybrid threats” as called for in the EC’s Strategic Plan 2021-2024. Addressing exactly these challenges, the overall objective of SECASSURED is to deliver innovative security engineering solutions with (AI-based) security services to achieve novel holistic assurance-driven security engineering, capable of (1) increasing software, hardware and supply chain security by identifying cybersecurity and regulatory risks while integrating (both commercial and open-source) components, even third party ones, (2) providing virtual, secure environments for the automated assessment of system components including AI components and their secure integration, and (3) continuous assurance-driven security engineering with a holistic toolbox of (AI-based) security services. It paves the way of secure continuous system integration of (third-party) components, including AI components, across the computing continuum, and implements EC's evolving security and privacy regulations, as well as the strategy of human-centric AI.

Keywords: security assurance,ai based security services,secdevops,digital twins,iot,edge,cloud,security testing and orchestration,vulnerability discovery,dynamic security assessment,explainable ai
Comprehensive search for new phenomena in the dilepton spectrum at the LHC (DITTO)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Fundamental Constituents of Matter
Panel description: Particle, nuclear, plasma, atomic, molecular, gas, and optical physics
Countries involved: France
Call: ERC CONSOLIDATOR GRANTS (ERC-2022-COG, 2022)
Start date: 2023-10-01
End date: 2028-09-30
Duration (months): 60.0
Total project cost (EUR): 1999409.0
EU funding (EUR): 1999409.0
Participants: 1
Project status: SIGNED

While the Standard Model of particle physics (SM) has proven tremendously successful, experimental evidence points to it not being a complete description of our universe, but a low energy approximation of a more complete theory. The searches for new phenomena (NP) are therefore an important component of the experimental program of the Large Hadron Collider (LHC). While there is no direct evidence for NP at the LHC, measurements of beauty hadron decays display a seemingly coherent pattern of deviations with respect to the SM predictions, which suggest that NP couples differently to three generations of matter. The quark-level processes responsible for these so-called ‘flavor anomalies’ are related to dilepton production processes (Drell-Yan scattering) through the crossing symmetry. The measurements of the kinematics of the high mass Drell-Yan (HMDY) process are therefore uniquely sensitive to a wide variety of NP explanations of the ‘anomalies’. The goal of this ground-breaking project is to provide for the first time the complete set of world’s most precise HMDY differential cross-section measurements covering not only the light lepton channels ev/μv/ee/µµ, but also extremely challenging third generation τv and ττ, ditau (DITTO), final states. These measurements will be used to probe NP at mass scales beyond the reach of direct production at the LHC through the SM effective field theory framework. The innovative performance and trigger improvements of the DITTO project will allow the ensemble of the proposed measurements to reach maximum precision, boosting the possibility for a NP discovery within the data sets expected to be collected by the ATLAS experiment at the LHC. Just as dilepton resonances, such as the J/ψ and Y mesons and the Z and W bosons were crucial for the establishment of the SM, the study of the same final state, to be undertaken in the DITTO project, will help to pave the way for a better understanding of the physics processes beyond it.
Reaction robot with intimate photocatalytic and separation functions in a 3-D network driven by artificial intelligence (CATART)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Spain,Netherlands,Italy,Germany,United Kingdom,Slovenia
Call: EIC Pathfinder Open 2021 (HORIZON-EIC-2021-PATHFINDEROPEN-01, 2021)
Start date: 2022-09-01
End date: 2026-08-31
Duration (months): 48.0
Total project cost (EUR): 2871775.0
EU funding (EUR): 2871775.0
Participants: 9
Project status: SIGNED

Mimicking the chemical production of nature is a well pursued dream in the scientific community. Scientific progress is limited by the lack of efficient synergies among complex functions and by a much smaller research library than nature. CATART will explore new synergies in reaction robots that mimic nature in a much faster way. This will be achieved using H2O and CO2 as model substrates. We propose systems containing 3-D quantum dot networks with the ability to simultaneously harvest sun-light by luminescence, photo-catalyze substrates and separate products. These phenomena will be managed by artificial intelligence, leading to reaction robots that autonomously learn and instantly maximize productivity. The envisioned system will revolutionize the way chemicals are produced. The combination of expertise in photonics, machine learning, catalysis, organic chemistry and engineering from 5 academic, 1 research center, 1 SME and 1 industrial partner will enable a successful pathway into feasible reaction robots. CATART will contribute to a game-changing chemical technology, placing EU industry and society in a privileged situation to face future economic and environmental constraints.

Keywords: chemical technology,robotics,photonics,solar fuels
Transforming Education with Emerging Technologies (TransEET)

Framework: Horizon Europe — Widening Participation and Strengthening the European Research Area
Programme: Widening participation and spreading excellence
Theme: Improved access to Excellence
Destination: Improved access to Excellence
Action type: Coordination and support actions
Countries involved: Greece,Netherlands,Austria,United Kingdom,Italy
Call: Twinning (HORIZON-WIDERA-2021-ACCESS-03, 2021)
Start date: 2023-01-01
End date: 2025-12-31
Duration (months): 36.0
Total project cost (EUR): 1328230.0
EU funding (EUR): 1328229.75
Participants: 5
Project status: SIGNED

TransEET will forge sustainable connections and synergies between a research Lab in the most historical University in Widening Greece and four respective highly impacting labs in leading institutions in Europe. It will address the problem of shaping the use of existing and emerging technologies, for dynamic educational transformation aiming to meet the needs of the 21st century. Education is an SSH research domain which has a lot to gain from twinning between widening countries and leading research teams with complementary expertise. Envisioning and shaping the future of education in the digital era is a persistently illusive endeavor exacerbated by loosely understood changing educational needs, emerging digital technologies and the unpredictability of societal, citizenship, mobility parameters. TransEET will significantly augment the research, leadership and impact capability of a Greek Lab with outstanding potential, yet hampered and slowed down by lagging experience in administration, management and capability for international impact. The project will establish a strategic program leading to the co-design, implementation and outreach of educational innovations with emerging technologies such as AI, VR, AR, 3D printing, in an equal pace and range across the partners. Twinning will be uniquely fueled by an original method called 'Co.F.E.' comprising of the following elements, a) creating four Communities of Interest involving diverse members and engaged in complementary joint enterprises (CoI), b) generating home-grown technologies affording a dense flow of useable rapid prototypes (FRP), and c) augmenting the CoI research actors' hybrid expertise to meet the interdisciplinary necessity to address this research field (AHE). The Co.F.E. method will aim to generate strong leadership capacity in a Greek institution, contribute to world-leading sustained research and innovation in a transforming Education sector, and impact on all the partners' educational contexts.

Keywords: educational transformation digital transformation multidisciplinarity steam education 21st century skills emerging technologies creativity design mathematics education computational thinking
Black Widow Antivenom Innovation Necessity (BWAIN)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Denmark
Call: ERC PROOF OF CONCEPT GRANTS1 (ERC-2022-POC1, 2022)
Start date: 2022-05-01
End date: 2023-10-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

Widow spiders are spread worldwide, and their bite induces severe envenomation symptoms that can lead to a complex syndrome known as latrodectism and death in severe cases. The only available specific treatment consists of polyclonal antibodies derived from horse plasma obtained by hyperimmunization with black widow spider venom. However, this process is slow, dangerous, and implies the continuous use of large domestic animals (mainly horses) in the manufacturing process. Venom unavailability is a significant supply chain bottleneck in antivenom manufacture, which imposes a very high product cost. Also, the efficacy of this horse-derived product suffers from batch-to-batch variation, resulting in variable efficacy profiles for different batches. Finally, the non-human nature of the horse-derived antibodies may provoke severe adverse immunological reactions. The high prevalence of adverse reactions severely limits its use, and antivenom use is thus reserved for only the most extreme cases, while not being administered at all to the many patients with asthma, atopy, or other allergy-related conditions. We are developing a recombinant antivenom based on a single broadly-neutralizing fully human monoclonal antibody that can neutralize the toxic effects of widow spider bites. According to WHO nomenclature, this antibody will be called Latrotoxumab, and it will be safer to administer, more efficacious, as well as cost-competitive with existing antivenoms. In this ERC PoC project, which is based on results obtained in the ERC StG project MABSTER (grant number 850974), we will explore the commercial potential of Latrotoxumab and lay the first foundation for a spin-off company (Fang Pharma) by securing in vivo PoC, securing IPR, developing a regulatory, manufacturing, and clinical trial plan, and preparing a fully-flexed business plan, incl. market, pricing, and SWOT analyses, identification of business growth opportunities (partners and investors), and exit strategy.
Reversing Tumor Immunotherapy Resistance via TME Modulation (REVIVE)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Germany
Call: ERC PROOF OF CONCEPT GRANTS (ERC-2025-POC, 2025)
Start date: 2026-01-01
End date: 2027-06-30
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: SIGNED

T cell infiltration and persistence in solid tumors are crucial for the success of T cell-based immunotherapies, yet the tumor microenvironment (TME) often suppresses T cell access and function. Our ERC-funded research has identified a G protein-coupled receptor (GPCR), activated by a metabolite commonly enriched in solid tumors, that substantially impairs T cells. We showed that inhibition of this GPCR enhances T cell infiltration, persistence, and cytotoxicity, thereby substantially improving the efficacy of CAR-T, TCR-T, and immune checkpoint blockade (ICB) therapies across tumor models of various cancer types. To advance these findings towards clinical applications, we developed monoclonal antibodies (mAb) against this GPCR, which exhibit potent blocking functions and high specificity. Our lead mAb effectively reactivates patient-derived tumor-infiltrating lymphocytes (TILs) against autologous primary tumor cells, underscoring its therapeutic potential. Project REVIVE aims to 1) humanize and optimize our mAbs target this GPCR, 2) conduct preclinical validation to assess efficacy and safety in advanced models, 3) develop predictive biomarkers for patient selection, and 4) establish a comprehensive intellectual property (IP) and commercialization strategy, integrating freedom to operate (FTO) analyses, market assessment, licensing opportunities, and industry partnerships to facilitate clinical translation. By executing these steps, REVIVE will generate an investor-ready, clinically viable, IP-protected antibody targeting this GPCR, supported by comprehensive preclinical validation and a biomarker-driven patient selection strategy. These outcomes will enhance the commercial attractiveness of our therapeutic candidate for licensing or spin-out opportunities, paving the way for future clinical translation and patient benefit.